Table 4.

Tumor ORR summary

CMR, n (%)PMR, n (%)NMR, n (%)PD, n (%)ORR, n (%)
Investigator assessment      
 Cohorts 1 and 2 (n = 6) 1 (17%) 3 (50%) 0 (0%) 2 (33%) 4 (67%) 
 Cohort 3 and extension (n = 24) 10 (42%) 11 (46%) 2 (8%) 1 (4%) 21 (88%) 
 Safety analysis set (n = 30) 11 (37%) 14 (47%) 2 (7%) 3 (10%) 25 (83%) 
Investigator assessment      
 Cohorts 1 and 2 (n = 5) 1 (20%) 2 (40%) 2 (40%) 0 (0%) 3 (60%) 
 Cohort 3 and extension (n = 24) 11 (46%) 10 (42%) 0 (0%) 3 (13%) 21 (88%) 
 Safety analysis set (n = 29) 12 (42%) 12 (42%) 2 (7%) 3 (10%) 24 (83%) 
CMR, n (%)PMR, n (%)NMR, n (%)PD, n (%)ORR, n (%)
Investigator assessment      
 Cohorts 1 and 2 (n = 6) 1 (17%) 3 (50%) 0 (0%) 2 (33%) 4 (67%) 
 Cohort 3 and extension (n = 24) 10 (42%) 11 (46%) 2 (8%) 1 (4%) 21 (88%) 
 Safety analysis set (n = 30) 11 (37%) 14 (47%) 2 (7%) 3 (10%) 25 (83%) 
Investigator assessment      
 Cohorts 1 and 2 (n = 5) 1 (20%) 2 (40%) 2 (40%) 0 (0%) 3 (60%) 
 Cohort 3 and extension (n = 24) 11 (46%) 10 (42%) 0 (0%) 3 (13%) 21 (88%) 
 Safety analysis set (n = 29) 12 (42%) 12 (42%) 2 (7%) 3 (10%) 24 (83%) 

PD, progressive disease.

Close Modal

or Create an Account

Close Modal
Close Modal